EGFR and heart failure: However, the results found that the reporting odds ratio for osimertinib compared with all other drugs was 5.4 for cardiac failure and 11.2 for QT prolongation, and compared with the 3 other EGFR TKIs, it was 2.2 for cardiac failure and 6.6 for QT prolongation (24).